Nantenine: An antagonist of the behavioral and physiological effects of MDMA in mice

Psychopharmacology

Volumn 173, Issue 3-4, 2004, Pages 270-277

  Fantegrossi, William E ^a   Kiessel, Christina Lynn ^a   Leach, P Tarn ^a   Van Martin, C ^a   Karabenick, Rachel Lynn ^a   Chen, X ^c   Ohizumi, Y ^c   Ullrich, Thomas ^b   Rice, Kenner C ^b   Woods, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Hyperthermia; MDMA; Nantenine; Toxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADRENERGIC RECEPTOR; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; NANTENINE; PRAZOSIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DETERMINATION; DRUG EFFECT; ENANTIOMER; HEAD TWITCH; HOUSING; HYPERTHERMIA; LETHALITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TELEMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; APORPHINES; BEHAVIOR, ANIMAL; CROWDING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEVER; FLUOROBENZENES; MALE; MICE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERIDINES; PRAZOSIN; SEROTONIN AGENTS; SEROTONIN ANTAGONISTS; STEREOISOMERISM;

EID: 2542619029     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1741-2     Document Type: Article

References (32)

1. Acquas E, Marrocu P, Pisanu A, Cadoni C, Zernig G, Saria A, DiChiara G (2001) Intravenous administration of ecstasy (3,4-methylenedioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 418:207-211
2. Battaglia G, Brooks B, Kulsakdinum C, DeSouza E (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-163
3. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Oison SB, Magenis RE, Amara SG, Grandy DK (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181-1188
4. Colpaert FC, Janssen PAJ (1983) The head twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 22:993-1000
5. 2 receptor-induced head-twitch behavior in mice. Eur J Pharmacol 186:115-118
6. 2 receptors? Pharmacol Biochem Behav 36:901-906
7. Darmani NA, Martin BR, Glennon RA (1992) Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. J Pharmacol Exp Ther 262:692-698
8. Drug Abuse Warning Network (2002) The DAWN report: club drugs, 2001 update, October. Office of Applied Studies, Substance Abuse, and Mental Health Services Administration, Washington, D.C.
9. 2A receptors are active under physiological conditions. Psychopharmacology 128:198-205
10. Fantegrossi WE, Ulrich T, Rice KC, Woods JH, Winger G (2002) 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161:356-364
11. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Woods JH (2003) Effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly-housed and crowded mice. Psychopharmacology 166:202-211
12. Fischer H, Zernig G, Schatz D, Humpel C, Saria A (2001) MDMA (ecstasy) enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 12:1385-1390
13. 2 receptors. Br J Pharmacol 84:743-755
14. 2 receptor antagonist pirenperone. Neuropharmacology 22:573-578
15. Handley SL, Singh L (1986) Neurotransmitters and shaking behavior: more than a "gut bath" for the brain. Trends Pharmacol Sci 7:324-328
16. Indra B, Tadano T, Nakagawasai O, Arai Y, Yasuhara H, Ohizumi Y, Kisara K (2002a) Suppressive effect of nantenine, isolated from Nandina domestica Thunberg. on the 5-hydroxy-L-tryptophan plus clorgyline-induced head-twitch response in mice. Life Sci 70:2647-2656
17. Indra B, Matsunaga K, Hoshino O, Suzuki M, Ogasawara H, Ishiguro M, Ohizumi Y (2002b) Structure-activity relationship on (±)-nantenine derivatives in antiseritonergic activities in rat aorta. Can J Physiol Pharmacol 80:198-204
18. 1-adrenoceptor antagonist activity. Eur J Pharmacol 437:173-178
19. 2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15:116-124
20. Lucki I, Nobler MS, Frazer A (1984) Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 228:133-139
21. McDaid J, Docherty JR (2001) Vascular actions of MDMA involve 1 and 2-adrenoceptors in the anaesthetized rat. Br J Pharmacol 133:429-439
22. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 18:305-313
23. Orallo F (2003) Pharmacological effects of (+)-nantenine, an alkaloid isolated from Platycapnos spicata, in several rat isolated tissues. Planta Medica 69:135-142
24. Ortmann R, Biscoff S, Radeke E, Bueche O, Delini-Stula A (1982) Correlation between different measures of antiserotonin activity of drugs. Naunyn Schmiedeberg's Arch Pharmacol 321:265-270
25. Pederson NP, Blessing WW (2001) Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J. Neurosci 21:8648-8654
26. Peroutka SJ, Lebovitz RM, Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science (Wash. DC) 212:827-829
27. +-p-NPPase activity. Phytomedicine. 8:107-111
28. Rothman R, Baumann M, Dersch C, Romero D, Rice K, Carroll F, Partilla J (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41
29. Rudnick G, Wall S (1992) The molecular mechanism of [3,4-methylenedioxy- methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89:1817-1821
30. Schmidt C, Levin J, Lovenberg W (1987) In vivo and in vitro neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36:747-755
31. Shoji N, Umeyama A, Takemoto T, Ohizumi Y (1984) Serotonergic receptor antagonist from Nandina domestica Thunberg. J Pharm Sci 73:568-570
32. Sprague JE, Banks ML, Cook VJ, Mills EM (2003) Hypothalamic-pituitary- thyroid axis and sympathetic nervous system involvement in the hyperthermia induced by 3,4-metbylenedioxymethamphetamine (MDMA, ecstasy). J Pharmacol Exp Ther 305:159-166